Crinetics Q4 2025: Palsonify launch revenue $5.4M, net loss $122.8M; EU CHMP positive opinion

Crinetics Pharmaceuticals, Inc.

2025-FY EPS reported -$4.95 revenue$7,696,000

PALSONIFY net product revenue $5.4M in Q4 2025; >200 enrollment forms by Dec end; 125+ HCPs prescribed in Q4.
CHMP adopted positive opinion recommending EU marketing authorization for paltusotine in acromegaly; EC decision pending.
Seamless Phase 2/3 EQUILIBRIUM study of atumelnant in Cushing's syndrome to start H1 2026; Phase 3 trials for CAH and carcinoid syndrome initiated.
Full-year 2025 net loss $465.3M; cash used $326.2M, below guidance; cash $1.0B at Dec 31, 2025 (pro forma $1.4B post Jan 2026 offering).
2026 GAAP OpEx guidance $600-650M; non-GAAP OpEx $480-520M; R&D and SG&A investments continue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.